{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:07:05Z","timestamp":1791403625132,"version":"4.3.3"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jaad.2014.08.027","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T22:15:22Z","timestamp":1429136122000},"page":"761-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Rosacea"],"prefix":"10.1016","volume":"72","author":[{"given":"Aimee M.","family":"Two","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiggin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tissa R.","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.08.027_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","article-title":"The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities","volume":"163","author":"Aksoy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1365-2133.2005.06895.x","article-title":"Comorbidity of\u00a0rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital\u00a0Ambulatory Care Survey\u2014outpatient department data collected by the U.S. National Center for Health Statistics\u00a0from 1995 to 2002","volume":"153","author":"Gupta","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2004.03.033","article-title":"Rosacea: II. Therapy","volume":"51","author":"Pelle","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib4","first-page":"725","article-title":"Diagnosis and treatment of rosacea: state of the art","volume":"11","author":"Baldwin","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1365-2133.2004.05985.x","article-title":"Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis","volume":"150","author":"Dirschka","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09546630601121078","article-title":"Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea","volume":"18","author":"Laquieze","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2014.08.027_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1396-0296.2004.04S1008.x","article-title":"Cleansing, moisturizing, and sun-protection regimens for normal skin, self-perceived sensitive skin, and dermatologist-assessed sensitive skin","volume":"17","author":"Hawkins","year":"2004","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2014.08.027_bib9","first-page":"16","article-title":"Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib10","first-page":"26","article-title":"Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib11","first-page":"663","article-title":"The pathophysiology of rosacea","volume":"144","author":"Mc Aleer","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.08.027_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2230.2003.01179.x","article-title":"The role of free oxygen radicals in the aetiopathogenesis of rosacea","volume":"28","author":"Oztas","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib13","first-page":"26","article-title":"Rosacea, reactive oxygen species, and azelaic acid","volume":"2","author":"Jones","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1211\/jpp.59.8.0010","article-title":"Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system","volume":"59","author":"Narayanan","year":"2007","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.jaad.2014.08.027_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/exd.12066","article-title":"Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARgamma","volume":"22","author":"Briganti","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib16","first-page":"531","article-title":"American Acne & Rosacea Society rosacea medical management guidelines","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib17","first-page":"43","article-title":"Standard management options for rosacea, part 1: overview and broad spectrum of care","volume":"84","author":"Odom","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib18","first-page":"234","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib19","first-page":"271","article-title":"A status report on the medical management of rosacea: focus on topical therapies","volume":"70","author":"Del Rosso","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656566.5.1.5","article-title":"Medical treatment of rosacea with emphasis on topical therapies","volume":"5","author":"Del Rosso","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2014.08.027_bib21","first-page":"29","article-title":"Evaluating the role of topical therapies in the\u00a0management of rosacea: focus on combination sodium\u00a0sulfacetamide and sulfur formulations","volume":"73","author":"Del Rosso","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2133.2011.10473.x","article-title":"Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review","volume":"165","author":"van Zuuren","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.1983.tb03972.x","article-title":"Treatment of rosacea with 1% metronidazole cream. A double-blind study","volume":"108","author":"Nielsen","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","article-title":"Topical metronidazole therapy for rosacea","volume":"123","author":"Bleicher","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib25","first-page":"44","article-title":"A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea","volume":"61","author":"Breneman","year":"1998","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib26","first-page":"283","article-title":"Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial","volume":"43","author":"Lowe","year":"1989","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1067\/mjd.2001.116219","article-title":"Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea","volume":"45","author":"Dahl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archderm.134.6.679","article-title":"Topical metronidazole maintains remissions of rosacea","volume":"134","author":"Dahl","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib29","first-page":"CD003262","article-title":"Interventions for rosacea","volume":"3","author":"van Zuuren","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.08.027_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-2008-1064456","article-title":"Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities","volume":"14","author":"Jansen","year":"1998","journal-title":"Facial Plast Surg"},{"key":"10.1016\/j.jaad.2014.08.027_bib31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/000155599750009906","article-title":"Double-blind comparison of\u00a0azelaic acid 20% cream and its vehicle in treatment of\u00a0papulo-pustular rosacea","volume":"79","author":"Bjerke","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.08.027_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety\u00a0of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF00372056","article-title":"Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases","volume":"283","author":"Akamatsu","year":"1991","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2014.08.027_bib34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2013.05.019","article-title":"Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel","volume":"69","author":"Coda","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/14740331003709736","article-title":"Brimonidine for glaucoma","volume":"9","author":"Rahman","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2014.08.027_bib36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib37","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib38","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jaad.2014.01.853","article-title":"Brimonidine effective but may lead to significant rebound erythema","volume":"70","author":"Ilkovitch","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib39","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2013.10.054","article-title":"Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%","volume":"70","author":"Routt","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib40","first-page":"1369","article-title":"Successful treatment of the erythema\u00a0and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline","volume":"143","author":"Shanler","year":"2007","journal-title":"Arch\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1046\/j.1365-4362.1998.00433.x","article-title":"Short- and long-term histologic effects of topical tretinoin on photodamaged skin","volume":"37","author":"Bhawan","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archderm.1991.01680040067005","article-title":"Topical tretinoin for treatment of photodamaged skin. A multicenter study","volume":"127","author":"Weinstein","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaad.2014.08.027_bib44","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.4049\/jimmunol.174.5.2467","article-title":"Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function","volume":"174","author":"Liu","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaad.2014.08.027_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archderm.1994.01690030051008","article-title":"A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea","volume":"130","author":"Ertl","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib46","first-page":"1410","article-title":"Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial","volume":"11","author":"Freeman","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib47","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1346-8138.2011.01223.x","article-title":"Pimecrolimus 1% cream\u00a0for\u00a0the treatment of rosacea","volume":"38","author":"Kim","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(03)02157-1","article-title":"Tacrolimus effect on rosacea","volume":"50","author":"Bamford","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib49","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1365-2133.2006.07669.x","article-title":"Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial","volume":"156","author":"Weissenbacher","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1468-3083.2008.02589.x","article-title":"A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea","volume":"22","author":"Karabulut","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.08.027_bib51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1468-3083.2003.00692.x","article-title":"Pimecrolimus: a review","volume":"17","author":"Gupta","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.08.027_bib52","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.0906-6705.2004.00269.x","article-title":"Pimecrolimus\u2014an anti-inflammatory drug targeting the skin","volume":"13","author":"Grassberger","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib53","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0190-9622(99)70022-8","article-title":"Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream","volume":"41","author":"Forstinger","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S1473-3099(08)70283-4","article-title":"Rosacea-like demodicidosis","volume":"8","author":"Larios","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaad.2014.08.027_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000065849","article-title":"Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study","volume":"205","author":"Kocak","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.08.027_bib56","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib57","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-4632.2008.03445.x","article-title":"Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial","volume":"47","author":"Akhyani","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib58","first-page":"703","article-title":"Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender","volume":"11","author":"Del Rosso","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib59","first-page":"1219","article-title":"Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type","volume":"11","author":"Alexis","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11204850-000000000-00000","article-title":"Doxycycline 40 mg capsules (30\u00a0mg\u00a0immediate-release\/10 mg delayed-release beads): anti-inflammatory dose in rosacea","volume":"11","author":"McKeage","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib61","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","article-title":"Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin","volume":"132","author":"Kanada","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12019-007-8003-x","article-title":"Submicrobial doxycycline and rosacea","volume":"33","author":"Wise","year":"2007","journal-title":"Compr Ther"},{"key":"10.1016\/j.jaad.2014.08.027_bib63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.det.2007.01.012","article-title":"Anti-inflammatory activity of tetracyclines","volume":"25","author":"Webster","year":"2007","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2014.08.027_bib64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000235550","article-title":"Tetracycline actions relevant to rosacea treatment","volume":"22","author":"Korting","year":"2009","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.jaad.2014.08.027_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2005.07.021","article-title":"Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol","volume":"53","author":"Craige","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib66","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/archdermatol.2011.204","article-title":"Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea","volume":"147","author":"Hsu","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker","volume":"67","author":"Hsu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib68","first-page":"673","article-title":"Rosacea: a review of current topical, systemic and light-based therapies","volume":"144","author":"Kennedy Carney","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.08.027_bib69","first-page":"54","article-title":"Use of oral isotretinoin in the management of rosacea","volume":"4","author":"Park","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib70","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archderm.134.7.884","article-title":"Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea","volume":"134","author":"Erdogan","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib71","first-page":"505","article-title":"Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study","volume":"8","author":"Gollnick","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.08.027_bib72","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/jid.2009.435","article-title":"Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid","volume":"130","author":"Morizane","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib73","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2012.111","article-title":"Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients","volume":"132","author":"Dispenza","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib74","first-page":"134","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea","volume":"93","author":"Del Rosso","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.08.027_bib75","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1096\/fj.06-6075com","article-title":"Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin","volume":"20","author":"Yamasaki","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jaad.2014.08.027_bib76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","article-title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2014.08.027_bib77","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/jid.2013.472","article-title":"Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor","volume":"134","author":"Two","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.08.027_bib78","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.4049\/jimmunol.170.5.2274","article-title":"Cutting edge: mast cell\u00a0antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide","volume":"170","author":"Di Nardo","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2014.08.027_bib79","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm1757","article-title":"Mast cell activators: a new class of highly effective vaccine adjuvants","volume":"14","author":"McLachlan","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2014.08.027_bib80","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2014.222","article-title":"Mast cells are key mediators of cathelicidin initiated skin inflammation in rosacea","volume":"134","author":"Muto","year":"2014","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221401874X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221401874X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:07Z","timestamp":1759271587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221401874X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S019096221401874X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.08.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosacea","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(15)01459-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}